These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21342047)

  • 21. The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.
    Tonyali O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2010 Nov; 11(16):2715-25. PubMed ID: 20977404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical value of bisphosphonates in cancer therapy.
    Lüftner D; Henschke P; Possinger K
    Anticancer Res; 2007; 27(4A):1759-68. PubMed ID: 17649770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bisphosphonates in oncology: rising stars or fallen heroes.
    Van den Wyngaert T; Huizing MT; Fossion E; Vermorken JB
    Oncologist; 2009 Feb; 14(2):181-91. PubMed ID: 19179412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical trials in metastatic breast cancer to bone: past--present--future.
    Body JJ
    Can J Oncol; 1995 Dec; 5 Suppl 1():16-27. PubMed ID: 8853520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anticancer properties of zoledronic acid.
    Green J; Lipton A
    Cancer Invest; 2010 Nov; 28(9):944-57. PubMed ID: 20879838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?
    Gnant M; Dubsky P; Fitzal F; Blaha P; Schoppmann S; Steger G; Marth C; Samonigg H; Hüttner K; Fohler H; Ruecklinger E; Jakesz R; Greil R;
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S18-27. PubMed ID: 19561003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-tumor potential of bisphosphonates.
    Green JR
    Med Klin (Munich); 2000 Oct; 95 Suppl 2():23-8. PubMed ID: 11089384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.
    Kyrgidis A; Triaridis S; Vahtsevanos K; Antoniades K
    Expert Rev Anticancer Ther; 2009 Aug; 9(8):1125-34. PubMed ID: 19671032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The evolving role of bone-conserving therapy in patients with breast cancer.
    Brufsky AM
    Semin Oncol; 2010 Jun; 37 Suppl 1():S12-9. PubMed ID: 20682367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moving into the future: treatment of bone metastases and beyond.
    Hortobagyi GN
    Cancer Treat Rev; 2005; 31 Suppl 3():9-18. PubMed ID: 16249057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence.
    Santini D; Stumbo L; Spoto C; D'Onofrio L; Pantano F; Iuliani M; Fioramonti M; Zoccoli A; Ribelli G; Virzì V; Vincenzi B; Tonini G
    Breast Cancer Res; 2015 Sep; 17(1):121. PubMed ID: 26328589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bisphosphonate anticancer activity.
    Tonini G; Vincenzi B; Santini D
    Expert Opin Pharmacother; 2011 Apr; 12(5):681-3. PubMed ID: 21385151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring the anti-tumour activity of bisphosphonates in early breast cancer.
    Winter MC; Holen I; Coleman RE
    Cancer Treat Rev; 2008 Aug; 34(5):453-75. PubMed ID: 18423992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease.
    Neville-Webbe HL; Coleman RE
    Eur J Cancer; 2010 May; 46(7):1211-22. PubMed ID: 20347292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current and future status of adjuvant therapy for breast cancer.
    Coleman RE
    Cancer; 2003 Feb; 97(3 Suppl):880-6. PubMed ID: 12548590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bisphosphonates for the prevention of bone metastases.
    Coleman RE
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):43-9. PubMed ID: 12584694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving progression-free and overall survival in patients with cancer: a potential role for bisphosphonates.
    Lipton A
    Expert Opin Pharmacother; 2011 Apr; 12(5):749-62. PubMed ID: 21247359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential anticancer properties of bisphosphonates: insights from preclinical studies.
    Clezardin P
    Anticancer Agents Med Chem; 2012 Feb; 12(2):102-13. PubMed ID: 21864232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials.
    Van Acker HH; Anguille S; Willemen Y; Smits EL; Van Tendeloo VF
    Pharmacol Ther; 2016 Feb; 158():24-40. PubMed ID: 26617219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitory effect of novel S,N-bisphosphonates on some carcinoma cell lines, osteoarthritis, and chronic inflammation.
    Kamel AA; Geronikaki A; Abdou WM
    Eur J Med Chem; 2012 May; 51():239-49. PubMed ID: 22444025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.